SpyGlass Pharma
SGP
35 hedge funds and large institutions have $655M invested in SpyGlass Pharma in 2026 Q1 according to their latest regulatory filings, with 35 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
75.85% more ownership
Funds ownership: 0% → 75.85% (+76%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$216M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$199M |
| 3 |
SCV
Sands Capital Ventures
Arlington,
Virginia
|
+$67.3M |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$56.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19M |
Top Sellers
SGP Hedge Fund Activity: Q1 2026 in Review
35 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in SpyGlass Pharma (SGP) for Q1 2026, worth a combined $655M.
Buyers outnumbered sellers: 35 funds opened new SGP positions and 0 closed out — a net gain of 35 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $216M.
- 35 institutional investors held SpyGlass Pharma (SGP) as of Q1 2026, up from 0 in Q4 2025.
- Funds reported $655M of SpyGlass Pharma stock for Q1 2026.
- 35 funds opened new SpyGlass Pharma positions in Q1 2026 and 0 closed out, a net change of +35 holders.
- The largest SpyGlass Pharma buyer in Q1 2026 was RA Capital Management, an estimated $216M added.
Based on aggregated 13F filings for Q1 2026.